Company profile
Fate Therapeutics, Inc.
NASDAQ: FATE · Healthcare · Biotechnology
#677 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
43DFH 30DQ 65GM 26SS 67
v0.1 · 65/100 weight · provisional
↑ disclosure history, market scale · ↓ 3-yr revenue growth, operating margin
Methodology →Revenue TTM
$6.3M
Rev growth YoY (TTM)
-52.6%
Net income (FY)
-$136.3M
Employees
161
as of 2026-08-12
Market cap
$319.4M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.6M$6.6M2025
Net income-$136.3M-$136.3M2025
Operating income-$147.7M-$147.7M2025
Total assets$318.9M$318.9M2025
Equity$207.2M$207.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
Upfront Fee And Equity Premium100%
By geography
Not disclosed.
The read
What is Fate Therapeutics, Inc.’s revenue?
Fate Therapeutics, Inc. booked $6.6M in FY2025 revenue, contracting 51% year over year — slower than 82% of Healthcare companies we track, at a -2051.1% net margin.
Peers · Healthcare
Medite Cancer Diagnostics, Inc.——Reliq Health Technologies Inc.——Pacific Health Care Organization, Inc.74BEvommune, Inc.46DEncision Inc.——GlobeImmune, Inc.——Neighbors
San Diego →Key facts
CEOBahram Valamehr
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: FATE
Employees161
IPO date2013-10-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.